Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$37.53M+91.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua J. Ofman
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 910
- Beta
- 3.25
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 4.54
Financials
Revenue
$37.53M+91.1%Net Income
$-103.57MEBITDA
$-98.85MFree Cash Flow
$-79.47MEPS (diluted)
$-2.21Shares Outstanding (diluted)
46.78M+50.6%Operating Expenses
$126.51MCash & Debt
$788.68MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $147.17M | $-408.35M | $-11.11 |
| 2024 | $125.59M | $-2.03B | $-63.54 |
| 2023 | $93.11M | $-1.47B | $-47.20 |
| 2022 | $55.55M | $-5.40B | $-173.87 |
| 2021 | $14.61M | $-1.25B | $-40.18 |
| 2020 | $0.00 | $-312.16M | $-2.52 |
| 2019 | $0.00 | $-244.85M | $-1.99 |
| 2018 | $0.00 | $-275.72M | $-2.42 |
Valuation
GRALhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-66.67%Social Signal Score
Mentions (36)
- Newsfool.com·21h ago·Negative
What's Behind Grail Stock's Wild Ride in 2026, and What Can Investors Expect in 2027? Food and Drug Administration approval is seen as a gateway to potential coverage by Medicare and commercial insurers for Grail's Galleri test. Pricing remains a key watch item, as it's far from clear how commercial insurers will value the test.
View source ↗ - News (RSS)investing·2d ago·Neutral
AI Takes On Cancer Detection From a Single Blood Draw (MEDS, ANT, GH, GRAL, NTRA, FRNM)
View source ↗ - Newsfool.com·3d ago·Positive
Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027? Grail is a leader in early cancer detection through its multi-cancer blood test, Galleri, which is currently undergoing large-scale clinical trials. Tempus AI operates a vast data ecosystem that utilizes artificial intelligence and genomics to provide precision medicine solutions for physicians and researchers.
View source ↗ - Newsfool.com·3d ago·Positive
GRAIL: 3 Key Takeaways for Long-Term Investors GRAIL completed over 174,000 Galleri tests during nine months of 2026. Third-quarter Galleri test volumes increased 24% over the prior year.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript GRAIL, Inc. ( GRAL ) 2026 UBS Global Healthcare Conference November 10, 2026 11:00 AM EST Company Participants Aaron Freidin - CFO & Head of Corporate Development Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning.
View source ↗ - News247wallst.com·13d ago·Neutral
Her Doctor Will Order a $949 Blood Test That Screens for Multiple Cancers. Medicare Will Pay $0 Toward the Test, Leaving Her With the Entire Bill Before Any Coverage Decision in 2029 Congress finally cleared a path for Medicare to cover a multi-cancer blood test, but a quirk in the fine print moves the goalposts every year. For one 70-year-old patient, the clock may never line up, and her doctor's next suggestion carries hidden costs.
View source ↗ - News (RSS)fool·17d ago·Negative
GRAIL (GRAL) Q3 2026 Earnings Call Transcript Promotional pricing lifted test volume sharply, but margins fell and losses widened.
View source ↗ - Newszacks.com·17d ago·Neutral
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.
View source ↗ - News (RSS)seekingalpha·17d ago·Positive
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·18d ago·Positive
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
What GRAIL (GRAL) Said on Its Q3 Earnings Call GRAIL NASDAQ: GRAL reported 4% revenue growth for the third quarter of 2026 as higher testing volumes were offset in part by lower prices, and said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027.
View source ↗ - Newsprnewswire.com·18d ago·Negative
… Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 Million SUNNYVALE, Calif., Nov. 4, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter of 2026.
View source ↗ - Newszacks.com·24d ago·Neutral
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
View source ↗ - Newsprnewswire.com·32d ago·Negative
GRAIL to Announce Third Quarter 2026 Financial Results SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2026 following the close of market on Wednesday, Nov. 4, 2026.
View source ↗ - Newsdefenseworld.net·35d ago·Negative
GRAIL (NASDAQ:GRAL) Stock Price Down 5.6% on Insider Selling GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)'s stock price dropped 5.6% on Friday after an insider sold shares in the company. The stock traded as low as $129.03 and last traded at $127.9350. 67,481 shares traded hands during trading, a decline of 93% from the average session volume of 971,234 shares. The stock had previously
View source ↗ - Newswsj.com·41d ago·Positive
First-Class Amenity Kits Have Become Holy Grail Collectibles For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.
View source ↗ - News (RSS)fool·42d ago·Neutral
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical.
View source ↗ - Newsfool.com·42d ago·Neutral
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's success.
View source ↗ - Newsprnewswire.com·48d ago·Neutral
…r Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom…
View source ↗ - News (RSS)fool·49d ago·Positive
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets analyst projections.
View source ↗ - Newsfool.com·49d ago·Positive
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.
View source ↗ - News (RSS)fool·53d ago·Positive
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October The cancer blood test maker could have a bright future.
View source ↗ - News (RSS)seekingalpha·55d ago·Neutral
GRAIL: AdCom's Vote Of Confidence Is Significant
View source ↗ - Newsdefenseworld.net·57d ago·Negative
Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00. Following the transaction, the chief financial officer owned 248,983 shares in the company,
View source ↗ - Newsfool.com·58d ago·Neutral
Here's Why Grail Stock Surged 55% This Week Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access. Galleri's efficacy vote was close, reflecting ongoing concerns about effectiveness.
View source ↗ - Newswsj.com·59d ago·Neutral
Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't? There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.
View source ↗ - Newswsj.com·60d ago·Neutral
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
View source ↗ - Newsreuters.com·60d ago·Neutral
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy A panel of outside experts advising the US FDA backed the safety of Grail's blood-based cancer detection test, Galleri, on Wednesday, but was divided on the evidence supporting its effectiveness.
View source ↗ - Newsseekingalpha.com·62d ago·Positive
GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade) GRAIL (GRAL) stock surges >30% as FDA briefing notes on Galleri cancer test signal optimism ahead of the AdCom meeting. Galleri's pivotal studies show high specificity (99.6%), PPV up to 77%, and reduced late-stage diagnoses, but sensitivity remains moderate. I assign GRAL a Buy rating, favoring FDA approval and further upside, yet acknowledge significant revenue, reimbursement, and competitive risks.
View source ↗ - Newsbarrons.com·62d ago·Negative
Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA The biotech meets with the Food and Drug Administration this week for premarket approval of its landmark cancer blood test.
View source ↗ - Newsfool.com·74d ago·Negative
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.
View source ↗ - Newsprnewswire.com·80d ago·Negative
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment wi…
View source ↗ - Newsprnewswire.com·83d ago·Negative
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.
View source ↗ - Newsmarketbeat.com·100d ago·Positive
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
GRAIL: Looking Beyond The NHS-Galleri Headline GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
View source ↗ - Newsbenzinga.com·104d ago·Negative
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $-2.38 per share
Typical surprise +17.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-2.21 vs $-2.56beat
- Wed, Aug 5$-2.56 vs $-2.66beat
- Tue, May 5$-2.29 vs $-2.76beat
- Thu, Feb 19$-2.44 vs $-3.33beat
- Wed, Nov 12$-2.46 vs $-3.36beat
- Tue, Aug 12$-3.18 vs $-3.14miss
Estimates and results for GRAL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GRAL officers and directors.
- Bought
- —
- Sold
- $143.9m
0 trades
67 trades
- Freidin Aaronsold
- Freidin Aaronsold
- Freidin Aaronsold
- Freidin Aaronsold
- Freidin Aaronsold
- Freidin Aaronsold
- Ofman Joshua J.sold
- Ofman Joshua J.sold
33 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GRAL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
